Skip to main content

Branded

  • Drug offerings expand under Merck Helps programs

    WHITEHOUSE STATION, N.J. Merck is expanding its patient assistance program, the drug maker said Wednesday.

  • FDA approves multiple sclerosis drug Gilenya

    SILVER SPRING, Md. The Food and Drug Administration has approved a drug for reducing relapses in patients with multiple sclerosis.

     

    The FDA announced Wednesday the approval of Swiss drug maker Novartis’ Gilenia (fingolimod) capsules, saying it was the first oral drug that can slow the progression of disability in patients with MS and offered an alternative to injected drugs.

     

     

    Around 400,000 people in the United States and 2.1 million worldwide have MS, according to the National Multiple Sclerosis Society.

  • Sanofi-Aventis, Paul and Mira Sorvino launch 'Diabetes Co-Stars' program

    BRIDGEWATER, N.J. Sanofi-Aventis has tapped actors Paul and Mira Sorvino to launch an awareness program aimed to help people living with diabetes and those who support them.

     

    The "Diabetes Co-Stars" program provides family and friends of diabetics with advice on lifestyle choices, healthy cooking, promoting physical activity and treatment options including insulin, Sanofi-Aventis said. DiabetesCoStars.com provides links to the Sanofi-Aventis diabetes social media pages, including Facebook and Twitter.

     

  • Amneal to open new distribution center

    GLASGOW, Ky. Amneal Pharmaceuticals will have a grand opening of its newly expanded distribution and sales center next week, the generic drug maker said Monday.

     

    Amneal announced the grand opening of the center in Glasgow, Ky., set to take place Monday. Representatives from the municipal and state governments, the Tennessee Valley Authority, state legislators and possibly members of Congress are expected to attend.

     

     

  • FDA advisory committee recommends approval of BI's atrial fibrillation drug

    RIDGEFIELD, Conn. A Food and Drug Administration advisory committee has recommended approval of a drug for patients with atrial fibrillation.

     

    The FDA cardiovascular and renal drugs advisory committee voted unanimously to recommend approval for Boehringer Ingelheim's Pradaxa (dabigatran etexilate), for preventing strokes in atrial fibrillation patients. For the last 50 years, warfarin has been the only oral anticoagulant drug available for this purpose.

     

     

  • FDA accepts NDA for Aricept patch

    WOODCLIFF LAKE, N.J. The Food and Drug Administration has accepted for review a regulatory approval application for a patch made by Eisai to treat Alzheimer’s disease, the drug maker said Friday.

     

    The agency will review a patch formulation of Aricept (donepezil hydrochloride), a weekly patch for treating mild, moderate and severe stages of the disease. The drug already is available in tablet form.

     

     

  • Sanofi-Aventis' WISE program gets recognition from HBA

    FAIRFIELD, N.J. The Healthcare Businesswomen’s Association has given the U.S. subsidiary of French drug maker Sanofi-Aventis its 2010 HBA ACE Award for building women’s leadership in the company, the HBA said Thursday.

     

  • Novo Nordisk featured in Working Mother's '100 Best Companies' list

    PRINCETON, N.J. Working Mother magazine has named drug maker Novo Nordisk one of the best companies in the country for family-friendly benefits, the company said Thursday.

     

    The U.S. subsidiary of the Danish drug maker was named a Working Mother 100 Best Company for programs designed to help families balance work-life needs, such as adoption reimbursement, health benefits, paid time off and assistance for families sending their kids to college.

     

     

X
This ad will auto-close in 10 seconds